Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Lake Bioscience CoSHSE:600866 -0.87%66 Debt-to-EBITDA is 9.86 as of Jun. 2026, which is 433% above its 10-year median of 1.85. GuruFocus rates SHSE:600866 with a GF Score™ of 66/100 and a GF Value™ of ¥5.90 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 303 Biotechnology companies, Star Lake Bioscience Co ranks worse than 93.4% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Star Lake Bioscience Co's Debt-to-EBITDA or its related term are showing as below:
SHSE:600866'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.51 Med: 1.85 Max: 20.41
Current: 20.41
During the past 13 years, the highest Debt-to-EBITDA Ratio of Star Lake Bioscience Co was 20.41. The lowest was -8.51. And the median was 1.85.
SHSE:600866's Debt-to-EBITDA is ranked worse than 93.4% of 303
companies
in the Biotechnology industry
Industry Median: 1.27
vs SHSE:600866: 20.41
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Star Lake Bioscience Co Debt-to-EBITDA Related Terms
Star Lake Bioscience Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600866 vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Star Lake Bioscience Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Lake Bioscience Co Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Star Lake Bioscience Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Star Lake Bioscience Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Star Lake Bioscience Co (SHSE:600866) has a Debt-to-EBITDA of 9.86 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Star Lake Bioscience Co. This is 433% above median its historical median of 1.85. According to the industry distribution chart, Star Lake Bioscience Co ranks #283 out of 303 companies in the Biotechnology industry, placing it in the top 93.4%.
Is Star Lake Bioscience Co's Debt-to-EBITDA too high?
Star Lake Bioscience Co's current Debt-to-EBITDA of 9.86 is 433% above median its 10-year median of 1.85. The Biotechnology industry median Debt-to-EBITDA is 1.27. Star Lake Bioscience Co's value of 9.86 is 676.4% above this industry median. Based on the distribution chart, Star Lake Bioscience Co ranks #283 out of 303 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Star Lake Bioscience Co has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Star Lake Bioscience Co's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Star Lake Bioscience Co ranks #283 out of 303 companies for Debt-to-EBITDA. This places Star Lake Bioscience Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.27. Star Lake Bioscience Co's value of 9.86 is 676.4% above this benchmark. While the company's 10-year median is 1.85 vs. the industry median of 1.27, Star Lake Bioscience Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.27, based on 303 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Lake Bioscience Co's current Debt-to-EBITDA of 9.86 is 676.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Star Lake Bioscience Co. For the Biotechnology industry, the median Debt-to-EBITDA is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Lake Bioscience Co's current Debt-to-EBITDA is 9.86, which is 433% above median its own 10-year median of 1.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Lake Bioscience Co stock overvalued right now?
Based on GuruFocus' analysis, Star Lake Bioscience Co (SHSE:600866) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.90, compared to a current price of ¥4.57 — trading 22.5% below its estimated fair value. The current Debt-to-EBITDA is 9.86, which is 433% above median its 10-year median of 1.85 and 676.4% above the Biotechnology industry median of 1.27. Star Lake Bioscience Co's overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Star Lake Bioscience Co (SHSE:600866), the current Debt-to-EBITDA is 9.86 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Lake Bioscience Co (SHSE:600866) Overvalued in 2026?
Based on GuruFocus' analysis, Star Lake Bioscience Co stock appears to be undervalued.
The current stock price of ¥4.57 is trading 22.5% below its estimated GF Value™ of ¥5.90.
GuruFocus considers Star Lake Bioscience Co to be Modestly Undervalued.
Key valuation signals for SHSE:600866:
Debt-to-EBITDA: 9.86 (433% above median its 10-year median of 1.85)
GF Value™: ¥5.90 vs. price of ¥4.57 (22.5% below fair value)
Industry Position: 676.4% above the Biotechnology median (#283 of 303)
No single metric tells the full story. See the SHSE:600866 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Lake Bioscience Co Inc is a China-based Pharmaceutical manufacturer. The company is mainly engaged in the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates. Products offered by the company include proline, guanosine, adenosine, adenine, adefovir dipivoxil, memantine hydrochloride, Proline, threonine, lysine, among others. Its products are used in food processing, feed processing, and pharmaceutical manufacturing. Star Lake sells its products through direct sales and distributors in China and overseas markets.
66GF Score
Get the complete analysis for SHSE:600866
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600866 has been successfully added to your 
